GlassScriptPhysician profile
Julia G Payne
NPI 1194987743
$5,097.35
in general payments reported to CMS, 2019-2025
42 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $502 · 2021: $826 · 2022: $1,470 · 2023: $803 · 2024: $158 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $653.17 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Electromed, INC. | $476.22 | 2021-2025 | Smartvest |
| Insmed, INC. | $460.97 | 2019-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $457.08 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.60 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $247.98 | 2020-2023 | Tyvaso |
| Genzyme Corporation | $245.93 | 2019-2023 | |
| Philips North America LLC | $236.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $222.19 | 2019-2023 | Tezspire, Symbicort, Fasenra |
| Jazz Pharmaceuticals INC. | $197.61 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $178.18 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $146.74 | 2022-2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $136.27 | 2019-2023 | |
| Gilead Sciences, INC. | $96.33 | 2019-2021 | |
| Inspire Medical Systems, INC. | $93.15 | 2023-2025 | Inspire |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $90.29 | 2019-2023 | Xolair, Esbriet |
| Mylan Specialty L.P. | $84.55 | 2019-2021 | |
| Grifols USA, LLC | $74.81 | 2020-2023 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $63.12 | 2021-2023 | Tezspire |
| Becton, Dickinson and Company | $55.74 | 2024 | Hemosphere |
| Shire North American Group INC | $42.70 | 2019 | |
| Circassia INC. | $41.60 | 2019-2020 | |
| Ambu INC. | $38.98 | 2025 | |
| Mallinckrodt Hospital Products INC. | $36.70 | 2021-2022 | |
| Pulmonx Corporation | $36.42 | 2020-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| 3b Medical, INC. | $33.91 | 2025 | Luna |
| Takeda Pharmaceuticals U.S.A., INC. | $32.11 | 2021-2023 | Glassia |
| Edwards Lifesciences Corporation | $31.99 | 2021-2023 | Hemosphere |
| Novartis Pharmaceuticals Corporation | $29.57 | 2019 | |
| Resmed Corp | $28.47 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $27.18 | 2023 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $26.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.26 | 2019 | |
| Advanced Respiratory, INC | $24.05 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $23.78 | 2021 | |
| Vapotherm INC | $20.34 | 2022 | |
| Tempus Ai, INC | $19.75 | 2025 | Xt Cdx |
| Axsome Therapeutics, INC. | $19.55 | 2022 | |
| Harmony Biosciences LLC | $16.47 | 2022 | |
| Abbvie INC. | $16.20 | 2021 | |
| Merck Sharp & Dohme LLC | $15.56 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.45 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.